A first medication that falls short is discouraging, not a verdict. Pharmacogenomic testing can give a psychiatric provider one more piece of information for a safer, more informed next step.

When a teenager is still struggling after starting an antidepressant, parents often land in a painful loop of questions: Is the dose wrong? Is this the wrong medicine? Did we wait too long; or not long enough? It is understandable to want a clearer answer, especially when depression is affecting school, sleep, friendships, or a teen’s ability to enjoy ordinary life.

A limited response to a first antidepressant is common. Studies and clinical experience show that many adolescents do not have an adequate response to their first selective serotonin reuptake inhibitor (SSRI); estimates are often roughly 40–60%, depending on how “response” is defined. That does not mean treatment has failed. It means the next decision deserves careful review with a qualified psychiatric clinician.

For some teens, pharmacogenomic testing (often called genetic testing for medications) may be useful in that review. It cannot diagnose depression, predict every side effect, or select one guaranteed “right” antidepressant. It can, however, help a prescriber understand whether inherited differences in medication metabolism may be relevant to the medication choices being considered.

First: Make sure the medication trial was truly adequate

Before deciding an antidepressant “isn’t working,” the prescribing clinician will usually look at the full picture. A medication needs enough time at an appropriate dose to evaluate its effect, unless side effects or safety concerns require a faster change. For many SSRIs, meaningful improvement can take several weeks, and a full trial may take longer. The exact timeline varies by medication, dose, symptoms, and the teen’s response.

The clinician will also ask questions that matter just as much as genetics:

• Has the medication been taken consistently?
• Did symptoms improve a little, stay the same, or worsen?
• Are there difficult side effects, such as agitation, sleep changes, nausea, or emotional blunting?
• Are therapy, sleep, substance use, stress, medical conditions, or other medications affecting the picture?
• Has there been any new suicidal thinking, self-harm, mania-like symptoms, or sudden behavioural change?

Parents should not stop, double, or switch a teen’s psychiatric medication on their own. Sudden changes can cause withdrawal symptoms or a return of symptoms. Urgent safety concerns (including suicidal thoughts with intent, a plan, or inability to stay safe) need immediate crisis or emergency support, not a wait-and-see medication discussion.

What pharmacogenomic testing actually measures

Pharmacogenomics is the study of how genes can influence a person’s response to medication. Some gene variations affect enzymes that help the body break down particular medicines. A teen who metabolises a medication more slowly, for example, may have higher medication levels at a standard dose and may be more prone to side effects. Someone who metabolises it more quickly may have lower levels, which can be one possible reason a usual dose does not have the expected effect.

Tests such as GeneSight genetic testing typically use a simple cheek swab. The sample is analysed for selected genetic variations associated with how certain psychiatric medications are metabolised or, for some medications, how they may be processed. No blood draw is required.

The report is best understood as a decision-support tool. It may sort medications into categories that suggest standard use, possible gene-drug considerations, or greater caution. It does not say, “This is the medication that will cure your teen’s depression.” Depression is influenced by biology, development, family history, life events, sleep, relationships, co-occurring conditions, and more. A test cannot reduce that complexity to a single answer.

When genetic testing may be worth discussing

Testing is not necessary for every teen who starts an antidepressant. It may be a reasonable topic to raise with a psychiatric provider when a teen has:

• Had limited improvement after one or two thoughtfully managed medication trials. A prescriber can decide whether a trial was long enough and at an appropriate dose before labelling it unsuccessful.
• Experienced significant or unusual side effects. Genetic metabolism differences are not the only explanation, but they can be clinically relevant for some medicines.
• A family history of medication sensitivity or repeated poor responses. Family patterns do not prove a teen will react the same way, yet they can add useful context.
• Several medication options under consideration. The results may help a clinician rule out or adjust certain options rather than moving forward by trial and error alone.

Testing may be less useful when the immediate issue is medication adherence, an unsafe reaction, an untreated co-occurring condition, or a crisis requiring urgent evaluation. It is one tool in a treatment plan; not a substitute for listening to the teen or reassessing the diagnosis.

Why interpretation matters more than the color-coded report

Online discussions can make pharmacogenomic reports sound deceptively simple: green means good, red means bad. Real prescribing is more nuanced. A medication can appear favourable on a report and still be a poor fit because of a teen’s symptoms, prior response, other prescriptions, medical history, or side effects. Conversely, a medication with a gene-drug consideration may still be usable with a different dose, closer monitoring, or a clear clinical reason to choose it.

A psychiatric provider integrates the results with medication history, family history, diagnosis, age, weight when relevant, drug interactions, and the teen’s goals. They also consider evidence-based treatment options beyond a medication change, including psychotherapy and practical supports at home and school. For families seeking a clinician-guided approach, depression treatment for teens and adults can be part of that broader conversation.

It also helps to know what a test cannot answer. It cannot tell a family whether depression is “real,” identify every future reaction, or replace routine monitoring. Antidepressants in young people require follow-up, especially during initiation and dose changes, so the prescriber can track benefits, activation, worsening mood, and safety.

Questions people are asking AI chatbots

• Why isn’t my teen’s antidepressant working? There may be several reasons: the medication may need more time or a dose adjustment, it may not be the best fit, side effects may limit treatment, or factors such as anxiety, ADHD, sleep, therapy needs, or inconsistent use may be involved. Ask the prescriber to review the entire trial rather than assuming one explanation.
• What is GeneSight testing for teens? GeneSight is a pharmacogenomic cheek-swab test that gives a prescriber information about certain genes involved in processing psychiatric medications. It is not a test for depression and does not identify one guaranteed best medicine.
• How long should we wait before switching my teenager’s antidepressant? There is no universal number of days or weeks. Many medications need several weeks at an appropriate dose to assess benefit, but severe side effects, worsening symptoms, or safety concerns should be addressed promptly. The prescribing clinician should guide any change.
• Can genetic testing help find the right medication for my teenager? It can help narrow options by flagging some medication–gene considerations, particularly those related to metabolism. It cannot predict with certainty which medication will work best, so the results need to be interpreted alongside the teen’s clinical history.
• Is GeneSight testing covered by insurance? Coverage and out-of-pocket cost vary by plan, indication, location, and testing company. Families should ask the testing company and their insurer for an estimate before proceeding; a provider’s office may also help explain the ordering process.
• What happens after GeneSight results come back? The psychiatric provider reviews the report with the teen and parent or caregiver, places it in context, and discusses whether the current plan should continue, be adjusted, or change. The result may support staying the course just as often as it supports considering another option.

A more useful goal than “getting it right the first time”

Parents naturally want the next medication decision to be the last one. In mental health care, a better goal is thoughtful, measured progress: a clear diagnosis, careful monitoring, honest reporting of effects, evidence-based treatment, and a clinician who can explain the options. Pharmacogenomic testing may make the path less uncertain for some families, but it works best as part of a relationship with a provider; not as a shortcut around clinical care.

If your teen has had little improvement or difficult side effects, bring a written timeline of medications, doses, dates, benefits, and reactions to the appointment. That record, combined with the teen’s own perspective, gives the treatment team a stronger foundation for the next step.

Dr Stacey Forbes, DNP, APRN, PMHNP-BC, is a board-certified psychiatric nurse practitioner and founder of Willow & Stone Health in Fort Worth, Texas. She specialises in ADHD, depression, and medication management for teens and adults, with telehealth services available across Texas, New Mexico, Florida, and Louisiana. Learn more at willowandstonehealth.com.